Quest Diagnostics and Catapult Health Provide Virtual Preventive Care Services for Employers During COVID-19 Pandemic and Beyond

First collaboration of virtual care provider and national laboratory provider features self-collected at-home specimen collection and mental health care support to empower diverse workforces to access health care safely

Clinical encounter also evaluates patients for risk of COVID-19

SECAUCUS, N.J., Oct. 27, 2020 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, and Catapult Health, the leading national provider of employer-sponsored Preventive Checkups, have formed a collaboration designed to help organizations facilitate virtual (telehealth) access to clinical services for their employees and adult dependents, with emphasis on reducing risks related to preventable chronic diseases.

Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)
Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

The first-of-its-kind collaboration specifically focuses on helping employers create a highly convenient and safe way for employees to access thorough and guideline driven preventive care and mental health support during the COVID-19 pandemic. Research shows many individuals are reluctant to seek in-person health care due to fear of contracting the SARS-CoV-2 virus, raising the prospect that untreated, preventable conditions will progress to more advanced disease.

“Social distancing and fear of contracting COVID-19 make it difficult for many individuals to access preventive care services from their healthcare providers. At the same time, employers recognize that at-home care, technology enabled options, including preventive care and screening, can be highly effective in enabling prevention and treatment of chronic diseases, supporting better workforce health and lower medical costs,” said Jay G. Wohlgemuth, M.D., Senior Vice President and Chief Medical Officer, and head of the company’s Employer Population Health programs. “Quest Diagnostics and Catapult Health have complementary capabilities that, together, will improve the ability of organizations to support their employees’ health by providing a patient-centric service that meets them where they are during the pandemic and beyond.”

The collaboration pairs insights from Quest’s biometric screenings offered at-home via specimen self-collection, at Quest’s Patient Service Centers, and at the worksite with Catapult Health’s new VirtualCheckup™ solution. The VirtualCheckup includes a video preventive care checkup to allow for confidential analysis and consultation with a nurse practitioner. Each checkup covers personal and family health history, Quest’s lab test and biometric data, prescription drug adherence, depression screening (PHQ-9), and concludes with the creation of a personal action plan to include referral into employer health and benefits programs. The consultation also screens for potential COVID-19 exposure, and individuals identified as at-risk may be directed to COVID-19 diagnostic testing services provided by Quest.

Health plans typically reimburse Catapult’s preventive care checkups as a covered annual preventive checkup, reducing medical costs for employers and the need for employees to visit a doctor for the checkup.

“When people skip doctor visits, the consequences can be grave in terms of poorer long-term outcomes and higher medical costs,” said David Michel, CEO of Catapult Health. “Because they sponsor much of the nation’s healthcare, employers end up absorbing these costs to a great degree. Our unique virtual care model is designed to change that by taking preventive care into employee’s homes, thereby solving for access

Read more

Cancer Diagnostics Market Research Report by Diagnostic Type, by Indication – Global Forecast to 2025

Cancer Diagnostics Market Research Report by Diagnostic Type (Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers), by Indication (Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, and Kidney Cancer) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 26, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Cancer Diagnostics Market Research Report by Diagnostic Type, by Indication – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05913709/?utm_source=GNW

The Global Cancer Diagnostics Market is expected to grow from USD 140,325.96 Million in 2019 to USD 221,237.88 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.88%.

Market Segmentation & Coverage:
This research report categorizes the Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Diagnostic Type, the Cancer Diagnostics Market studied across Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers.

Based on Indication, the Cancer Diagnostics Market studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.

Based on Geography, the Cancer Diagnostics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Diagnostics Market including Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson & Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic Inc., Illumina Inc., Philips Healthcare, Qiagen NV, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc..

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and

Read more

US Home Diagnostics for Urinary Tract Infection Market Forecast to 2027

The US home diagnostics for urinary tract infection market is expected to reach US$ 444. 91 million by 2027 from US$ 267. 44 million in 2019; it is expected to grow at a CAGR of 6. 7% from 2020 to 2027.

New York, Oct. 26, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “US Home Diagnostics for Urinary Tract Infection Market Forecast to 2027 – COVID-19 Impact and Country Analysis By Form Type and Distribution Channel” – https://www.reportlinker.com/p05978942/?utm_source=GNW

The growth of the market is attributed to the key factors such as the growing UTI prevalence and increasing geriatric population. However, inaccuracy in the results of home UTI screening tests is the major factor hindering its market.

Advancements in the global healthcare sector and increasing emphasis on self care as well as preventive care lead to the emergence of home-based diagnostics.The medical device manufacturers focus on the implementation of new designs and prototypes to offer significant care to patients at home.

Home diagnostics confer improved patient care and experience and superior patient convenience, and incur lower cost.Moreover, the introduction of advanced diagnostics products for UTI detection is also projected to increase the adoption of home diagnostics products in the coming years.

Further, the increasing emphasis of government authorities to encourage home care provides significant opportunities for the growth of the market players.As per the American Urological Association, November is Bladder Health Awareness Month that serves as a reminder to Americans to gain the knowledge about common bladder health conditions and proactively take initiatives to take care of bladder health.

National Health Observance, the Urology Care Foundation sponsored by the US Department of Health and Human Services, is the world’s leading nonprofit urological health foundation.

Based on form type, the US home diagnostics for urinary tract infection market is segmented into dipsticks, cups, dipslides, cassettes, and others.In 2019, the dipsticks segment held the largest share of the market and is anticipated to register the highest CAGR during the forecast period.

Based on distribution channel, the US home diagnostics for urinary tract infection market is segmented into retail pharmacies and drug stores, supermarkets/hypermarkets, and online pharmacies.The retail pharmacies and drug stores segment held the largest share of the market in 2019.

The market for online pharmacies is anticipated to grow at the fastest CAGR during the forecast period.

A few of the major primary and secondary sources referred to while preparing this report on the US home diagnostics for urinary tract infection market are Chronic Kidney Disease (CKD), National Statistics Institute (NSI), Food and Drug Administration (FDA), and Centers for Disease Control and Prevention (CDC).
Read the full report: https://www.reportlinker.com/p05978942/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Source Article

Read more